Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kun Xiang

Cardiovascular Disease Ocala, FL Medical Doctor

NPI 1144451873 CMS profile 1341053

3310 Sw 34Th St, Ocala, FL 34474

Open in the dashboard

General payments

$94,272

448 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$30,932 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Kun Xiang of Ocala, FL is reported in the CMS Open Payments database as having received $94,272 across 448 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $30,932 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,420 93
2024 General $24,823 97
2023 General $20,768 80
2022 General $10,110 55
2021 General $17,121 44
2020 General $3,274 31
2019 General $7,755 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kun Xiang
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Kun Xiang were reported at $10,420. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Kun Xiang Cardiovascular Disease median Middle half National median
2019 $7,755 $450 $127–$1,392 $163
2020 $3,274 $242 $77–$751 $114
2021 $17,121 $335 $101–$1,037 $132
2022 $10,110 $395 $121–$1,211 $149
2023 $20,768 $443 $136–$1,283 $160
2024 $24,823 $450 $136–$1,323 $164
2025 $10,420 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Atricure, Inc. $32,415 37 payments
  2. Biotronik Inc. $26,594 115 payments
  3. Abbott Laboratories $17,620 137 payments
  4. Medtronic Vascular, Inc. $6,045 43 payments
  5. Boston Scientific Corporation $3,800 39 payments
  6. AltaThera Pharmaceuticals LLC $3,287 5 payments
  7. Medtronic, Inc. $1,875 31 payments
  8. Biosense Webster, Inc. $718 13 payments
  9. Medical Device Business Services, Inc. $468 3 payments
  10. Aziyo Biologics, Inc. $428 7 payments
  11. Other $1,022 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $55,580 133 payments
  2. Consulting Fee $19,575 7 payments
  3. Food and Beverage $18,432 306 payments
  4. Honoraria $500 1 payment
  5. Education $185 1 payment
Products named General payments · program years 2019–2025
  1. SYNERGY ABLATION SYSTEM $16,205 14 payments
  2. AtriCure cryoICE cryoSPHERE Cryoablation System $11,283 3 payments
  3. Solia $6,849 18 payments
  4. Acticor 7 VR-T DX $5,650 10 payments
  5. ENSITE PRECISION $5,570 40 payments
  6. BioMonitor $5,101 11 payments
  7. Edora 8 DR-T $4,481 7 payments
  8. Rivacor 7 DR-T $4,481 7 payments
  9. EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX $3,715 15 payments
  10. Sotalol Hydrochloride $3,287 5 payments
  11. Other $38,284 259 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

945

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$270,082

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

30.6%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 193 $196,516
Entresto Sacubitril/Valsartan Brand 42 $38,091
Multaq Dronedarone Hcl Brand 12 $15,844
Xarelto Rivaroxaban Brand 12 $10,942
Metoprolol Succinate Generic 156 $2,233
Midodrine Hcl Generic 18 $1,717
Amiodarone Hcl Generic 92 $1,286
Atorvastatin Calcium Generic 43 $425
Losartan Potassium Generic 61 $396
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 16 $381

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 65 billing codes

Paid by Medicare

$199,954

Medicare's payments for the services billed

Medicare patients

993

Average age 76

Services billed

3,417

460 women, 533 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 61%
Ischemic heart disease 55%
Arthritis 55%
Heart failure 49%
Chronic kidney disease 37%
Diabetes 34%
Depression 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Sotalol Hydrochloride
  • AltaThera Pharmaceuticals LLC $2,766
$2,766 14 —
Repatha
  • Amgen Inc. $144
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

448 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record